Metvixia

Metvixia is a brand name of methyl aminolevulinate topical, approved by the FDA in the following formulation(s):

METVIXIA (methyl aminolevulinate hydrochloride - cream; topical)

• 
  Manufacturer: GALDERMA LABS LP
  
  Approval date: July 27, 2004
  
  Strength(s): EQ 16.8% BASE ^[RLD]

Has a generic version of Metvixia been approved?

No. There is currently no therapeutically equivalent version of Metvixia available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Metvixia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
  Patent 6,034,267
  Issued: March 7, 2000
  Inventor(s): Gierskcky; Karl E. & Moan; Johan & Peng; Qian & Steen; Harald & Warloe; Trond & Bjorseth; Alf
  Assignee(s): PhotoCure AS
  The invention provides a pharmaceutical compositions comprising a compound of formula I: EQU R.sub.2.sup.2 N--CH.sub.2 COCH.sub.2 --CH.sub.2 CO--OR.sup.1(I) wherein, R.sup.1 and R.sup.2 have any of the values defined in the specification; or a salt thereof; and a pharmaceutically acceptable carrier or excipient. The invention also provides a method for the diagnosis or photochemotherapeutic treatment of disorders or abnormalities of external or internal surfaces of the body using such compounds or salts.
  
  Patent expiration dates:
  
  
  • March 8, 2016
    
    ✓ 
    Patent use: TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • June 26, 2011 - USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS
  
  

See also...

• Metvixia Consumer Information (Drugs.com)
• Metvixia Cream Consumer Information (Wolters Kluwer)
• Metvixia topical Consumer Information (Cerner Multum)
• Metvixia Advanced Consumer Information (Micromedex)
• Methyl Aminolevulinate Cream Consumer Information (Wolters Kluwer)
• Methyl aminolevulinate topical Consumer Information (Cerner Multum)
• Methyl aminolevulinate Topical application Advanced Consumer Information (Micromedex)